Phase II Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection, NEOSTAR/INDUCTION - Strategic Alliance: BMS
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jun 2017 Planned End Date changed from 1 Jul 2021 to 1 Jun 2021.
- 12 Jun 2017 Planned primary completion date changed from 1 Jul 2021 to 1 Jun 2021.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.